We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mesa Laboratories Inc | NASDAQ:MLAB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 105.52 | 84.00 | 167.77 | 0 | 09:09:30 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
NOVEMBER 6, 2018 (
OCTOBER
30
, 201
8
)
Date of Report (Date of earliest event reported)
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
COLORADO
|
0-11740 (Commission File Number) |
84-0872291
|
12100 WEST SIXTH AVENUE,
LAKEWOOD, COLORADO
|
|
80228
|
Registrant’s telephone number, including area code : (303) 987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|_| |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|_| |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|_| |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|_| |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
On October 30, 2018, the Registrant filed a Current Report on Form 8-K disclosing the voting results of its Annual Meeting of Shareholders of Mesa Laboratories, Inc. This filing failed to include the results for the election of Gary M. Owens as director. This first amendment provides that information below. No other amendments to the Current Report on Form 8-K filed on October 30, 2018, are being made by this Form 8-K/A.
ITEM 5.07 |
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |
The Annual Meeting of Shareholders of Mesa Laboratories, Inc. was held on October 30, 2018. Of the 3,850,775 shares of common stock entitled to vote, 3,485,171 were represented either in person or proxy. Eight directors were elected to serve until the next Annual Meeting of Shareholders. The advisory vote to approve executive compensation was approved. The ratification of the appointment of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the year ending March 31, 2019 was approved.
The eight directors elected were:
For |
Withheld |
Broker Non-Votes |
||||||||||
John B. Schmieder |
2,845,267 | 56,502 | 583,402 | |||||||||
John J. Sullivan, Ph.D. |
2,831,217 | 70,552 | 583,402 | |||||||||
Michael T. Brooks |
2,809,144 | 92,625 | 583,402 | |||||||||
H. Stuart Campbell |
2,628,589 | 273,180 | 583,402 | |||||||||
Robert V. Dwyer |
2,825,591 | 76,178 | 583,402 | |||||||||
Evan C. Guillemin |
2,838,366 | 63,403 | 583,402 | |||||||||
David M. Kelly |
2,835,171 | 66,598 | 583,402 | |||||||||
Gary M. Owens |
2,850,535 | 51,234 | 583,402 |
The advisory vote to approve executive compensation was approved by the following vote:
For | Against | Abstain |
Broker Non-Votes |
||||||||||
2,670,965 | 77,575 | 153,229 | 583,402 |
The appointment of EKS&H LLLP as the Company’s independent registered public accounting firm for the year ending March 31, 2019 was approved by the following vote:
For | Against | Abstain |
Broker Non-Votes |
||||||||||
3,445,902 | 23,845 | 15,424 | -- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: November 6, 2018 |
|
|
Mesa Laboratories, Inc. (Registrant) |
|
/s/ Gary M. Owens | ||||
BY: | Gary M. Owens, | |||
President and Chief Executive Officer |
1 Year Mesa Laboratories Chart |
1 Month Mesa Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions